Literature DB >> 15661244

Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer.

Tak-Hong Cheung1, Keith Wing-Kit Lo, So-Fan Yim, Cho-Sun Poon, Albert Yu-Kiu Cheung, Tony Kwok-Hung Chung, Yick-Fu Wong.   

Abstract

OBJECTIVES: We studied the loss of heterozygosity (LOH) in chromosome 1 in squamous cell carcinoma (SCC) of the uterine cervix and evaluated its clinical and pathological significance.
METHODS: Sixty-three highly polymorphic markers were used to study the LOH in 84 SCC. Microdissection was performed to enrich the tumor cells population before the alleotyping study. The findings were correlated with clinicopathologic findings.
RESULTS: LOH was detected in all but one SCC. The number of loci showing LOH in each case ranged from 0 to 41. Five loci showed LOH in > or =30% SCC and 28 other loci had an LOH frequency between 20% and 30%. Six of the eight markers located at 1p36.21 to 1p36.33 had a frequency of LOH >20%. Shortened total survival was associated with LOH at 14 loci and shortened disease-free survival was associated with LOH at 11 loci while LOH at nine loci were associated with both. A high frequency of LOH was associated with stage as well as shortened total and disease-free survival.
CONCLUSIONS: LOH is a common and early event in the development of cervical SCC. Tumor suppressor genes may be present at 1p36. The incidence of LOH increases as the tumor progresses but a high frequency of LOH is not an independent prognostic factor.

Entities:  

Mesh:

Year:  2005        PMID: 15661244     DOI: 10.1016/j.ygyno.2004.10.035

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

2.  The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.

Authors:  Assaf Vestin; Alea A Mills
Journal:  Gene Expr Patterns       Date:  2013-10-09       Impact factor: 1.224

Review 3.  Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors:  Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  The quest for the 1p36 tumor suppressor.

Authors:  Anindya Bagchi; Alea A Mills
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

5.  The MYCN oncogene is a direct target of miR-34a.

Authors:  J S Wei; Y K Song; S Durinck; Q-R Chen; A T C Cheuk; P Tsang; Q Zhang; C J Thiele; A Slack; J Shohet; J Khan
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

6.  Silencing of CHD5 gene by promoter methylation in leukemia.

Authors:  Rui Zhao; Fanyi Meng; Nisha Wang; Wenli Ma; Qitao Yan
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

7.  A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer.

Authors:  Garima Sharma; Pradeep Dua; Subhash Mohan Agarwal
Journal:  Curr Genomics       Date:  2014-08       Impact factor: 2.236

8.  Investigation of Cervical Tumor Biopsies for Chromosomal Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in HIV-1/HPV Co-infected Women.

Authors:  Ramadhani Chambuso; Evelyn Kaambo; Lynette Denny; Clive M Gray; Anna-Lise Williamson; Monika Migdalska-Sęk; Gloudi Agenbag; George Rebello; Raj Ramesar
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.